WT161

WT161 is a potent inhibitor of HDAC6 with an IC50 value of 0.40 nM. It is selective for HDAC6 over HDAC3 (IC50 = 51.61 nM) and induces alpha-tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC50 values ranging from 1.5 to 4.7 µM. WT161 enhances the cytotoxicity of bortezomib (Cay-10008822) and carfilzomib (Cay-17554) against patient-derived multiple myeloma cells. It also decreases tumor size in a human MM.1S multiple myeloma mouse xenograft model when administered in combination with bortezomib at doses of 50 and 0.5 mg/kg, respectively.Formal Name: 8-(hydroxyamino)-8-oxo-octanoic acid, 2-[[4-(diphenylamino)phenyl]methylene]hydrazide. CAS Number: 1206731-57-8. Molecular Formula: C27H30N4O3. Formula Weight: 458.6. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 10 mg/ml, DMSO: 10 mg/ml, DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml. lambdamax: 247, 291, 362 nm. SMILES: ONC(CCCCCCC(N/N=C/C(C=C1)=CC=C1N(C2=CC=CC=C2)C3=CC=CC=C3)=O)=O. InChi Code: InChI=1S/C27H30N4O3/c32-26(15-9-1-2-10-16-27(33)30-34)29-28-21-22-17-19-25(20-18-22)31(23-11-5-3-6-12-23)24-13-7-4-8-14-24/h3-8,11-14,17-21,34H,1-2,9-10,15-16H2,(H,29,32)(H,30,33)/b28-21+. InChi Key: KXWWYFKVBFUVIZ-SGWCAAJKSA-N.